Cargando…

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The increasing prevalence of NAFLD mirrors that of obesity and type 2 diabetes over the last two decades. MAIN: In a two-way pathophysiologic relationship, NAFLD increases the risk of developing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomah, Shaheen, Alkhouri, Naim, Hamdy, Osama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275502/ https://www.ncbi.nlm.nih.gov/pubmed/32518675 http://dx.doi.org/10.1186/s40842-020-00097-1

Ejemplares similares

Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2018)

Treatment of Nonalcoholic Fatty Liver Disease: Where do we Stand? An Overview
por: Dajani, Asad, et al.
Publicado: (2016)

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
por: Alkhouri, Naim, et al.
Publicado: (2018)

Multidisciplinary intensive lifestyle intervention improves markers of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes and obesity: a retrospective matched-cohort study
por: Tomah, Shaheen, et al.
Publicado: (2023)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Plasma Free Fatty Acids and Metabolic Effect in Type 2 Diabetes, an Ancillary Study from a Randomized Clinical Trial
por: Mitri, Joanna, et al.
Publicado: (2021)

Fatty Liver and Fatty Heart—Where do They Stand in the AMIS Syndrome?
por: Lautt, W. Wayne, et al.
Publicado: (2015)

Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease
por: Tabbaa, Adam, et al.
Publicado: (2015)

Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)
por: Alkhouri, Naim, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
por: Mitrovic, Bojan, et al.
Publicado: (2022)

The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease
por: Alkhouri, Naim, et al.
Publicado: (2014)

Fat Versus Carbohydrate-Based Energy-Restricted Diets for Weight Loss in Patients With Type 2 Diabetes
por: Hamdy, Osama, et al.
Publicado: (2018)

Vaccine for Diabetes—Where Do We Stand?
por: Chellappan, Dinesh Kumar, et al.
Publicado: (2022)

Transient Neonatal Diabetes: An Etiologic Clue for the Adult Diabetologist
por: Novak, Anela, et al.
Publicado: (2020)

Where Do We Stand?
Publicado: (1891)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
por: Khoudari, George, et al.
Publicado: (2019)

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
por: Alkhouri, Naim, et al.
Publicado: (2022)

Where do we stand on human diabetic nephropathy?
por: Ryong Cha, Dae
Publicado: (2013)

Precision diabetes: Where do we stand today?
por: Mohan, Viswanathan, et al.
Publicado: (2018)

Diabetic kidney disease, revisited: where do we stand?
por: Cha, Dae Ryong
Publicado: (2022)

Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States
por: Alkhouri, Naim, et al.
Publicado: (2022)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Role of Endoscopic Ultrasound in Liver Disease: Where Do We Stand?
por: Pavic, Tajana, et al.
Publicado: (2021)

COVID-19 and liver injury: where do we stand?
por: Papadopoulos, Nikolaos, et al.
Publicado: (2020)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Assessment of Liver Function With MRI: Where Do We Stand?
por: Río Bártulos, Carolina, et al.
Publicado: (2022)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Effect of diabetes-specific nutrition formulas on satiety and hunger hormones in patients with type 2 diabetes
por: Mottalib, Adham, et al.
Publicado: (2019)

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
por: Harrison, Stephen A., et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2018)

Dupuytren’s disease: where do we stand?
por: Grazina, Rita, et al.
Publicado: (2019)

Screening for gestational diabetes in India: Where do we stand?
por: Mohan, V, et al.
Publicado: (2015)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Where do conventional OADs stand
por: Sahay, Rakesh Kumar, et al.
Publicado: (2012)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Frequency of self-monitoring of blood glucose in relation to weight loss and A1C during intensive multidisciplinary weight management in patients with type 2 diabetes and obesity
por: Tomah, Shaheen, et al.
Publicado: (2019)

The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Our Response to COVID-19 as Endocrinologists and Diabetologists
por: Kaiser, Ursula B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ko365kg0m6tgpbq4er4mgnj7cf